Financials from Cannara Biotech Inc.'s company filings · Latest period: 2026-Q3 (ended )
Revenue
$31.83M
+16.4% vs a year earlier
Net income
$4.84M
Operating cash flow
$5.68M
Cash
$21.81M
Cannara Biotech Inc. specializes in the indoor cultivation, processing, and sale of cannabis and cannabis-derived products in Canada. The company exhibits strong financial health with a gross margin of 47.2% and an EBITDA margin of 28.2%, indicating efficient operations. However, its return on equity (ROE) of 3.8% and market cap of $201.52M suggest potential concerns regarding profitability and valuation relative to its margins. Additionally, while the current ratio of 3.00 reflects solid liquidity, the stock's recent decline of 2.39% may signal market apprehension.
Loading financial metrics...
Gross profit margin decreased from 44.6% to 38.5% compared to last year.
Strong revenue growth of 15.4% YoY indicates solid business momentum.
Operating cash flow of $18.9M exceeds net income by 74%, indicating high-quality earnings with strong cash conversion.
Strong cash flow conversion with 16.0% of revenue converting to operating cash.
Excellent liquidity with current ratio of 3.0x ensures operational stability.
Strong free cash flow margin of 16.0% provides substantial resources for dividends, buybacks, or reinvestment.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Drug Manufacturers - Specialty & Generic companies of a similar size
Based on 2026-Q3 (May 31, 2026)